

JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 71, ISSUE 6, PAGES 1061–1278

FROM THE EDITOR'S DESK

From the Editor's Desk . . .

R. Moreau, R. Bataller, T. Berg, S. Lotersztajn, J. Zucman-Rossi and R. Jalan 1061

EDITORIALS

Journal of Hepatology: The Home of Liver Research, 2015–2019

R. Jalan, R. Bataller, T. Berg, S. Lotersztajn, R. Moreau, J. Zucman-Rossi and J. Walicki 1065

DAA failures in African patients with “unusual” HCV subtypes: Hey! Didn't you know there was another world?

J.-M. Pawlotsky 1070

Adipose tissue-associated cancer risk: Is it the fat around the liver, or the fat inside the liver?

G. Marchesini, M.L. Petroni and H. Cortez-Pinto 1073

RESEARCH ARTICLES

Viral Hepatitis

Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting

R.K. Dhiman, G.S. Grover, M. Premkumar, S. Taneja, A. Duseja, S. Arora, S. Rath, S. Satsangi, A. Roy and MMPHCRF Investigators 1076

Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection

S. Faure-Dupuy, M. Delphin, L. Aillot, L. Dimier, F. Lebossé, J. Fresquet, R. Parent, M.S. Matter, M. Rivoire, N. Bendriss-Vermare, A. Salvetti, D. Heide, L. Flores, K. Klumpp, A. Lam, F. Zoulim, M. Heikenwälder, D. Durantel and J. Lucifora 1086

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C

K. Childs, C. Davis, M. Cannon, S. Montague, A. Filipe, L. Tong, P. Simmonds, D. Smith, E.C. Thomson, G. Dusheiko and K. Agarwal 1099

Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure

E. Degasperi, A. Spinetti, A. Lombardi, S. Landonio, M.C. Rossi, L. Pasulo, P. Pozzoni, A. Giorgini, P. Fabris, A. Romano, L. Lomonaco, M. Puoti, M. Vinci, F. Gatti, G. Carolo, A. Zoncada, P. Bonfanti, F.P. Russo, A. Aghemo, A. Soria, R. Centenaro, F. Maggiolo, P. Rovere, F. Pasin, V. Paon, G. Faggiano, A. Vario, G. Grossi, R. Soffredini, C. Carriero, S. Paolucci, F. Noventa, A. Alberti, P. Lampertico, S. Faggioli and NAVIGATORE-Lombardia and Veneto Study Groups 1106

Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations

C. Rossi, D. Jeong, S. Wong, G. McKee, Z.A. Butt, J. Buxton, J. Wong, M. Darvishian, S. Bartlett, H. Samji, A. Yu, M. Binka, M. Alvarez, P.A. Adu, M. Tyndall, M. Kraiden, N.Z. Janjua and for the BC Hepatitis Testers Cohort Team 1116

Cirrhosis

FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis

M. Sorribas, M.O. Jakob, B. Yilmaz, H. Li, D. Stutz, Y. Noser, A. de Gottardi, S. Moghadamrad, M. Hassan, A. Albillos, R. Francés, O. Juanola, I. Spadoni, M. Rescigno and R. Wiest 1126

Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia

M. Serra-Burriel, I. Graupera, P. Torán, M. Thiele, D. Roulot, V. Wai-Sun Wong, I. Neil Guha, N. Fabrellas, A. Arslanow, C. Expósito, R. Hernández, G. Lai-Hung Wong, D. Harman, S. Darwish Murad, A. Krag, G. Pera, P. Angeli, P. Galle, G.P. Aithal, L. Caballeria, L. Castera, P. Ginès, F. Lammert and on behalf of the investigators of the LiverScreen Consortium 1141

Cancer

Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence

S.-L. Zhou, Z.-J. Zhou, Z.-Q. Hu, C.-L. Song, Y.-J. Luo, C.-B. Luo, H.-Y. Xin, X.-R. Yang, Y.-H. Shi, Z. Wang, X.-W. Huang, Y. Cao, J. Fan and J. Zhou 1152

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

J. Ricke, H.J. Klumpfen, H. Amthauer, I. Bargellini, P. Bartenstein, E.N. de Toni, A. Gasbarrini, M. Pech, M. Peck-Radosavljevic, P. Popovič, O. Rosmorduc, E. Schott, M. Seidensticker, C. Verslype, B. Sangro and P. Malfertheiner 1164

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients

F. Tovoli, L. Ielasi, A. Casadei-Gardini, A. Granito, F.G. Foschi, G. Rovesti, G. Negrini, G. Orsi, M. Renzulli and F. Piscaglia 1175

Natural history of liver adenomatosis: A long-term observational study

L. Barbier, J.-C. Nault, F. Dujardin, B. Scotto, M. Besson, A. de Muret, P. Bourlier, J. Zucman-Rossi, E. Salamé and Y. Bacq 1184

Molecular and Cell Biology

Integrin β_1 -enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH

Q. Guo, K. Furuta, F. Lucien, L.H. Gutierrez Sanchez, P. Hirsova, A. Krishnan, A. Kabashima, K.D. Pavelko, B. Madden, H. Alhuwaish, Y. Gao, A. Revzin and S.H. Ibrahim 1193

IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells

Y. Wei, D. Shi, Z. Liang, Y. Liu, Y. Li, Y. Xing, W. Liu, Z. Ai, J. Zhuang, X. Chen, Q. Gao and J. Jiang 1206

Genetic and Metabolic Diseases

Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development

J. Mouries, P. Brescia, A. Silvestri, I. Spadoni, M. Sorribas, R. Wiest, E. Miletì, M. Galbiati, P. Invernizzi, L. Adorini, G. Penna and M. Rescigno 1216

The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity – A longitudinal cohort study

A.M. Allen, S.B. Hicks, K.C. Mara, J.J. Larson and T.M. Therneau 1229

SPECIAL SECTIONS

Grand Rounds

Ursodeoxycholic acid in pregnancy?

E. de Vries and U. Beuers 1237

Hepatology Snapshot

Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease

B.K. Abu Dayyeh, F. Bazerbachi, I. Graupera and A. Cardenas 1246

LETTERS TO THE EDITOR

High tolerance of hepatitis B virus to thermal disinfection

A. König, T.T. Than, D. Todt, S.K. Yoon, J. Steinmann, E. Steinmann and M.P. Windisch 1249

Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis

L. Lapointe-Shaw, P.C. Austin, H. Chung, B. Sander, J.C. Kwong and J.J. Feld 1251

Reply to: “Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis”

M. Alavi, M.G. Law and G.J. Dore 1254

Reply to: “Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis”

J. Wilton, H. Samji, A. Yu, M. Krajden, N.Z. Janjua and for the BC Hepatitis Testers Cohort team 1256

In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients

J.T. Blackard, A. Kwara and K.E. Sherman 1259

Reply to: “In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.”

J.-H. Lee and K.-H. Kim 1260

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

S.A. Khan, T. Genus, H. Morement, A. Murphy, B. Rous and D. Tataru 1261

Reply to: “Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma”

P. Bertuccio, M. Malvezzi, G. Carioli, D. Hashim, P. Boffetta, H.B. El-Serag, C. La Vecchia and E. Negri 1262

Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B

L.Z. Liu and J. Sun 1263

Antiviral treatment for hepatitis B in infancy: Still an issue for debate

H.-L. Chen, Y.-H. Ni, P.-J. Chen and M.-H. Chang 1264

Reply to: Correspondence relating to the manuscript “Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B”

P. Zhao 1265

Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007–2014

R. Desai, S. Singh, D. Zalavadia, P. Bansal and H. Goyal 1266

Reply to: “Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007–2014”

J. von Felden, V. Mallet and S. Pischke 1268

Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes

B. Vrancken, L. Cuyppers, A.B. Pérez, N. Chueca, J. Anton-Basantas, A. de la Iglesia, J. Fuentes, J.A. Pineda, F. Téllez, E. Bernal, P. Rincón, M.A. Von Wichman, A. Fuentes, F. Vera, A. Rivero-Juárez, M. Jiménez, A.-M. Vandamme and F. García 1270

Reply to: “Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes”

J. Macías 1272

Assessment of liver phenotype in adults with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype)

J. Kümpers, M. Fromme, C.V. Schneider, C. Trautwein, H. Denk, K. Hamesch and P. Strnad 1272

Reply to: "Assessment of liver phenotype in adults with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype)"

G.W. Marek III, M. Brantly and V.C. Clark 1274

Potential role of ketamine in burn-associated cholestasis

L. Meunier, M. Meszaros, G.-P. Pageaux and D. Larrey 1275

Reply to: "Potential role of ketamine in burn-associated cholestasis"

M. Legrand, C. de Tymowski, K. Hodjat and V. Mallet 1276

CORRIGENDUM

Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543–552]

T. Yau, C. Hsu, T.-Y. Kim, S.-P. Choo, Y.-K. Kang, M.-M. Hou, K. Numata, W. Yeo, A. Chopra, M. Ikeda, R. Kuromatsu, M. Moriguchi, Y. Chao, H. Zhao, J. Anderson, C. Dela Cruz and M. Kudo 1278

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

The cover of this issue celebrates the completion of the current Editorial team's 5-year term (2015–2019) in charge of the Journal. The artwork illustrates that the success of this period was the result of the work of all members of the Journal of Hepatology community. This is represented by a "castell", a human tower traditionally built at festivals in Catalan regions every "casteller" in the base or upper part of the tower is essential to lift the "castell" into the air. Concept: Ramon Bataller; Production: Editorial office; Artwork: Marcelo Daniel Castro.